πŸ“Š This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Syros

1.1 - Company Overview

Syros Logo

Syros

Headquarter: United States
Founded: 20XXπŸ”’
Employees: 100-500πŸ”’
🌐 Website

Company description

  • Provider of a gene control platform that systematically analyzes regulatory regions of the genome to develop small-molecule medicines that control gene expression, and developer of oral therapeutics including tamibarotene (selective RARΞ± agonist) in clinical development for genomically defined HR-MDS and AML, and previously clinical assets SY-2101 (oral arsenic trioxide for APL) and SY-5609 (CDK7 inhibitor for pancreatic cancer).

Products and services

  • Gene Control Platform: A genomics-driven platform that systematically analyzes regulatory regions of the genome to engineer small-molecule medicines controlling expression of genes critical to a given cell
  • Tamibarotene: A clinical-stage, oral selective retinoic acid receptor alpha (RARΞ±) agonist in development for genomically defined subsets of higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML)
  • SY-2101: A novel oral arsenic trioxide (ATO) form previously in clinical development for patients with acute promyelocytic leukemia (APL), enabling APL treatment via oral ATO administration

Key contacts

πŸ”’
πŸ”’

Financial details

πŸ”’

1.2 - Competitors and similar companies to Syros

Synlogic Logo

Synlogic

HQ: United States Website
  • Description: Provider of synthetic biotic medicines designed to perform metabolic functions to treat diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Synlogic company profile β†’
Genomics Logo

Genomics

HQ: United Kingdom Website
  • Description: Provider of health-tech solutions leveraging genetic data to estimate disease risk, enable early detection, and support drug discovery.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Genomics company profile β†’
Rome Therapeutics Logo

Rome Therapeutics

HQ: United States Website
  • Description: Provider of novel therapies for cancer and autoimmune diseases harnessing the repeatome, including development of LINE-1 reverse transcriptase inhibitors for autoimmune diseases, supported by a data science platform that identifies active elements in the dark genome and assesses their roles in disease to guide drug development.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Rome Therapeutics company profile β†’
Ethris Logo

Ethris

HQ: Germany Website
  • Description: Provider of mRNA therapeutics and LNP delivery solutions focused on respiratory diseases and vaccines. Offers the SNIM RNA platform for stabilized non-immunogenic mRNA therapies and the SNaP LNP platform for targeted, inhalable delivery. Pipeline includes ETH47, ETH42, and ETH45 for respiratory indications. Provides in-house and partnered manufacturing with HPLC-free processes.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Ethris company profile β†’
Dicerna Logo

Dicerna

HQ: United States Website
  • Description: Provider of biotechnology research focused on discovering and developing RNA interference (RNAi)-based treatments for rare inherited liver diseases, cancers, and other liver-related conditions.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Dicerna company profile β†’
πŸ”’

2.M&A buyers

2.1 Potential strategic acquirers in the sector

πŸ”’
πŸ”’
πŸ”’
πŸ”’ View all strategic buyers with complete profiles
Start Free Trial β†’

2.2 - Strategic buyer groups for Syros

πŸ”’

Buyer group 1: β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ

●● companies
Description: β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ
Key Products: β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ
πŸ”’ View all companies in this group
Request Free Trial Now β†’
πŸ”’

Buyer group 2: β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ

●● companies
Description: β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ
Key Products: β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ
πŸ”’ View all companies in this group
Request Free Trial Now β†’
πŸ”’

Buyer group 3: β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ

●● companies
Description: β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ
Key Products: β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ
πŸ”’ View all companies in this group
Request Free Trial Now β†’
πŸ”“ Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β†’

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Syros

2.2 - Growth funds investing in similar companies to Syros

πŸ”’ View all growth equity funds with complete profiles
Start Free Trial β†’

4 - Top valuation comps for Syros

4.2 - Public trading comparable groups for Syros

πŸ”“ Unlock all public trading comparable groups with complete valuation data
Start Free Trial β†’

4.3 - M&A Transactions similar to Syros

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
πŸ”’ View all M&A transactions with complete deal terms
Request Free Trial Now β†’

Frequently Asked Questions

About Syros

What does Syros do?

Syros is a provider of a gene control platform that systematically analyzes regulatory regions of the genome to develop small-molecule medicines that control gene expression, and developer of oral therapeutics including tamibarotene (selective RARΞ± agonist) in clinical development for genomically defined HR-MDS and AML, and previously clinical assets SY-2101 (oral arsenic trioxide for APL) and SY-5609 (CDK7 inhibitor for pancreatic cancer).

Who are Syros's competitors?

Syros's competitors and similar companies include Synlogic, Genomics, Rome Therapeutics, Ethris, and Dicerna.

Where is Syros headquartered?

Syros is headquartered in United States.

How many employees does Syros have?

Syros has 1,000 employees πŸ”’.

When was Syros founded?

Syros was founded in 2010 πŸ”’.

What sector and industry vertical is Syros in?

Syros is in the Enterprise Software πŸ”’ sector and industry

M&A Buyers & Acquirers for Syros

Who are the top strategic acquirers in Syros's sector and industry

Top strategic M&A buyers and acquirers in Syros's sector include β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, and β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ πŸ”’.

Which M&A buyer groups are most relevant for Syros?

Top strategic M&A buyers groups and sectors for Syros include β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ , β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, and β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ πŸ”’.

Financial Investors investing in Syros's sector and industry vertical

Which are the top PE firms investing in Syros's sector and industry vertical?

Top PE firms investing in Syros's sector and industry vertical include β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, and β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ πŸ”’.

Who are the top buyout funds acquiring in Syros's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Syros's sector and industry vertical include β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, and β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ πŸ”’.

Who are the top growth equity funds investing in companies in Syros's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Syros include β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, and β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ πŸ”’.

Valuation benchmarks of companies in Syros's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Syros?

The key public trading comparables and valuation benchmarks for Syros include β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ, and β–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆβ–ˆ πŸ”’.

Which are the key trading comparable groups for Syros for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Syros with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Syros's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Syros with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Syros's' sector and industry vertical?

Access recent funding rounds and capital raises in Syros's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Syros

Launch login modal Launch register modal